Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
J Thorac Oncol. 2010 Apr;5(4):517-20. doi: 10.1097/JTO.0b013e3181d0a44b.
The aim of this study is to compare the outcomes of sleeve lobectomy (SL) and pneumonectomy (PN) and to determine which one is more acceptable standard procedure for patients with non-small cell lung cancer.
From 1996 to 2005, 424 patients underwent SL (n = 157) and PN (n = 267) in our institution. Propensity score matching analysis was performed to compare these two groups for mortality, morbidity, survival, recurrence, and postoperative pulmonary function.
In each group, 105 patients were eligible for analysis. The operative mortality was lower in the SL group (1.0%) than the PN group (8.6%), (p < 0.0001). The morbidity was similar (33.4% versus 29.5%, p = 0.376). The 5-year survival was lower in the PN group (PN, 32.14% versus SL, 58.43%, p = 0.0002). The recurrence pattern (locoregional versus distant) did not differ between two groups (p = 0.180). The mean actual postoperative first second forced expiratory volume in the patients underwent SL was 2.05 +/- 0.55 liter, which increased by 7.9% compared with the predicted-postoperative first second forced expiratory volume.
Our results showed that the SL can be performed with low operative risk and may offer superior survival and better postoperative pulmonary function compared with the PN in selected patients. If anatomically feasible, a SL must be considered as a favorable alternative to PN in patients with non-small cell lung cancer.
本研究旨在比较肺叶切除术(SL)和全肺切除术(PN)的结果,并确定哪一种手术对非小细胞肺癌患者更具可接受的标准。
1996 年至 2005 年,我院共对 424 例患者实施了 SL(n = 157)和 PN(n = 267)。采用倾向评分匹配分析比较两组患者的死亡率、发病率、生存率、复发率和术后肺功能。
每组各有 105 例患者符合分析条件。SL 组的手术死亡率(1.0%)明显低于 PN 组(8.6%)(p < 0.0001)。两组发病率相似(33.4%对 29.5%,p = 0.376)。PN 组 5 年生存率(PN 组 32.14%,SL 组 58.43%,p = 0.0002)较低。两组复发模式(局部区域复发与远处转移)无差异(p = 0.180)。SL 组患者术后实际第一秒用力呼气量平均为 2.05 +/- 0.55 升,比预计术后第一秒用力呼气量增加了 7.9%。
我们的研究结果表明,SL 手术具有低手术风险,如果解剖学上可行,在选择的患者中,与 PN 相比,SL 可能提供更好的生存和更好的术后肺功能。对于非小细胞肺癌患者,SL 必须被视为一种优于 PN 的有利选择。